Mandragora

Sustained tachycardia from muscarinic blockade increases cardiac workload. In patients with coronary artery disease, the documented heart rates of 170–190 bpm could precipitate myocardial ischemia or infarction.

Sustained tachycardia reduces diastolic filling time and increases myocardial oxygen demand, both of which worsen heart failure. Documented SVT at 170–190 bpm from Mandragora poisoning would be poorly tolerated in heart failure patients.

Mandragora alkaloids produce dose-dependent tachycardia via muscarinic blockade. Case reports document SVT at 170–190 bpm persisting for up to 5 days. Pre-existing arrhythmia substantially increases risk of hemodynamic compromise.

Scopolamine is metabolized primarily via CYP3A4 in the liver with oral bioavailability of only 3–27% due to first-pass effect. Hepatic impairment would reduce first-pass metabolism, substantially increasing systemic alkaloid exposure and prolonging effect duration. Liver enzyme elevation was documented in a Mandragora poisoning case (Tsiligianni 2009), normalizing over 10 days.

Scopolamine is documented to cross the placental barrier. While pharmaceutical scopolamine is considered non-teratogenic, the uncontrolled and unpredictable alkaloid exposure from wild-harvested Mandragora preparations, combined with risk of severe maternal anticholinergic toxidrome, constitutes a contraindication.

Older adults have well-documented enhanced sensitivity to anticholinergic agents. A case of severe scopolamine toxicity via transdermal patch was documented in a 66-year-old patient (Knuf 2019). Anticholinergic burden in elderly is associated with cognitive decline and increased dementia risk.

Children are particularly vulnerable to anticholinergic poisoning, with lower thresholds for severe toxidrome including delirium, hyperthermia, and seizures. This is well established in pharmaceutical anticholinergic toxicology, though no Mandragora-specific pediatric cases were identified.

First-generation antihistamines (diphenhydramine, chlorpheniramine), Tricyclic antidepressants (amitriptyline, nortriptyline), Antipsychotics (chlorpromazine, olanzapine), Urological agents (oxybutynin, tolterodine)

Co-administration with any agent possessing anticholinergic properties produces additive or synergistic muscarinic blockade, substantially increasing risk of severe anticholinergic toxidrome. This is a well-established pharmacodynamic interaction class.

Donepezil, Rivastigmine, Galantamine

Mandragora alkaloids directly antagonize the therapeutic mechanism of cholinesterase inhibitors used in dementia treatment, reducing efficacy of both the cholinesterase inhibitor and creating risk of anticholinergic breakthrough. This dual-harm scenario is clinically significant in dementia patients.

Muscarinic antagonism produces mydriasis, which in susceptible individuals with narrow anterior chamber angles can precipitate acute angle-closure glaucoma — a medical emergency. This is a standard contraindication for all anticholinergic agents.

Muscarinic blockade reduces detrusor muscle contractility, causing urinary retention. In patients with pre-existing urinary obstruction or prostatic hypertrophy, this can precipitate acute urinary retention requiring catheterization.